Adipose-derived mesenchymal stem cell-conditioned medium and proliferation of intestinal stem cells in mesenteric
Ryo Yamamoto1, Sayuri Suzuki1, Koichiro Homma2
1Department of Emergency and Critical Care Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
Abstract:
Mesenteric ischemia frequently causes bowel necrosis even after recirculation, known as reperfusion injury, and no effective therapy has been validated for preserving the intestine. Adipose-derived mesenchymal stem cell-conditioned medium (MSC-CM), a tissue engineering and regenerative therapy, has been suggested as a feasible acute-phase treatment for organ damages. This study aimed to elucidate the therapeutic effects of MSC-CM on intestinal tissue injuries by ischemia and reperfusion. Mice were categorized into three groups that underwent either 60-min mesenteric artery occlusion (ischemia group), 60-min reperfusion following 60-min occlusion (reperfusion group), or ischemia-reperfusion with the same duration following intravenous administration of 200-µL MSC-CM by retroorbital injection (MSC-CM group). The distal ileum was harvested, and immunofluorescence staining with caspase-3 and LGR5, an intestinal stem cell-specific marker, was performed for evaluating the injury location and type of cells protected by MSC-CM. Moreover, LGR5, Notch1, Jagged 1, Hes1, DLL1, DLL3, and DLL4 mRNA expressions were measured using quantitative polymerase chain reaction. Ischemia extensively damaged the epithelial layer, and reperfusion-induced cellular apoptosis at the epithelial layer. MSC-CM administration was associated with preservation of cells at the crypt base, which were identified as intestinal stem cells using double-immunofluorescence staining. The MSC-CM group demonstrated significantly higher LGR5 expression than the reperfusion and ischemia groups. Similarly, the MSC-CM group exhibited higher Notch1 and Jag1 expressions, whereas the reperfusion group showed a higher Notch1 expression. In conclusion, MSC-CM use was associated with preservation of the intestinal stem cells at the crypt of villi and higher Notch1 and Jag1 expressions.
Insights
Adipose-derived mesenchymal stem cell-conditioned medium (MSC-CM) protects intestinal stem cells from ischemia-reperfusion injury. MSC-CM therapy preserved intestinal stem cells and promoted healing, offering a potential treatment for bowel damage.
Area of Science:
- Regenerative Medicine
- Gastroenterology
- Stem Cell Biology
Background:
- Mesenteric ischemia often leads to bowel necrosis due to reperfusion injury, with no effective therapies currently available.
- Adipose-derived mesenchymal stem cell-conditioned medium (MSC-CM) is a promising regenerative therapy for organ damage.
- The therapeutic potential of MSC-CM in mitigating intestinal ischemia-reperfusion injury requires further investigation.
Purpose of the Study:
- To investigate the therapeutic effects of MSC-CM on intestinal tissue injury induced by ischemia and reperfusion.
- To evaluate the impact of MSC-CM on intestinal stem cell preservation and related molecular pathways.
Main Methods:
- Mice underwent 60-minute mesenteric artery occlusion (ischemia) or ischemia followed by 60-minute reperfusion.
- The MSC-CM group received MSC-CM intravenously after ischemia-reperfusion.
- Immunofluorescence staining (caspase-3, LGR5) and quantitative PCR (LGR5, Notch1, Jagged 1, Hes1, DLL1-4) were performed on distal ileum tissues.
Main Results:
- Ischemia damaged the epithelial layer; reperfusion induced apoptosis. MSC-CM preserved cells at the crypt base, identified as intestinal stem cells.
- MSC-CM administration significantly increased LGR5 expression compared to ischemia and reperfusion groups.
- The MSC-CM group showed elevated Notch1 and Jagged 1 mRNA expression, indicating potential involvement in stem cell signaling.
Conclusions:
- MSC-CM effectively preserves intestinal stem cells at the crypt of villi following ischemia-reperfusion injury.
- MSC-CM treatment upregulates key components of the Notch signaling pathway (Notch1, Jag1), suggesting a mechanism for intestinal protection.
- MSC-CM represents a potential therapeutic strategy for managing intestinal damage caused by mesenteric ischemia and reperfusion.

